Cancer diagnostics hub

Cancer diagnostics market analysis and updates

The global cancer burden is increasing. With precision oncology entering mainstream care, more patients are undergoing biomarker testing for cancer treatment in order to access more targeted and effective therapies.

Clearstate offers cancer diagnostics market data, forecasts, and trend predictions to give you insight on this fast-growing healthcare sector. Our cancer diagnostics hub is regularly updated to share our findings on the current state of oncology diagnostics and the impact of developments such as a growing global cancer burden and the rise of precision care on the future of tests for cancer IVDs.

Inquire now

What are cancer diagnostics?

Cancer diagnostics or lab tests used in cancer diagnosis range from tissue-based tests to molecular testing. Today, a wide range of cancer in vitro diagnostics (IVD) tests are available, including immunoassays, tissue-based tests, PCR-based molecular diagnostics, liquid biopsy and next generation sequencing (NGS).

Explore the latest cancer diagnostic testing market insights

From market news to analysis of cancer diagnostics, our articles provide concise and up-to-date information about latest innovations which are opening up new possibilities for cancer testing and treatment. Uncover the challenges and opportunities ahead as cancer lab tests play an important role in combating the rising global cancer burden.

What are the infrastructure, reimbursement levels, affordability and availability of oncology tests and IVDs that influence a country or region’s access? How is the patient journey for cancer diagnosis and treatment using biomarkers changing? What are the top cancer biomarkers and test strategies? How is the cancer diagnostics market size and demand changing?

Larger gene panels are the predominant NGS testing strategy in EU5

The growing number of biomarkers for which oncologists need information for treatment decision-making has necessitated a shift toward more comprehensive genomic profiling through next-generation sequencing (NGS).

Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019

Across Europe, there are varying levels of laboratory infrastructure capacity supporting NGS testing and integration of NGS testing in cancer care.

Precision medicine and access to NGS cancer biomarker testing in Europe

Advancements in cancer biomarker testing through the use of powerful molecular testing technologies such as next-generation sequencing (NGS) is supporting the use of precision medicine.

Future of Pathology: Four Growth Areas in Tissue Diagnostics

Various technologies and advancements in tissue diagnostics (TDx) will drive greater efficiency in pathology which is crucial for delivering improved cancer care and diagnosis amid the growing global cancer burden.

Tissue-based companion diagnostics market to grow for the most common cancers in China

Companion diagnostics (CDx) use is growing as the cancer treatment paradigm-shifts towards immunotherapy and targeted therapy.

Understand the cancer diagnostics market

Discover more IVD insights and learn how our IVD Gateway solutions can help prepare your business to support the drive to integrate the use of IVDs into regional or national plans to fight cancer.

Cancer and tissue diagnostics market outlook

Tissue diagnostics (TDx) play an important role in improving treatment and health outcomes for cancer patients. A global effort to tackle the disease amid a growing cancer burden and rapid advances in treatment, drives the increased demand for TDx solutions.

Next-generation sequencing (NGS) in cancer biomarker testing: testing trends in Europe labs

Europe’s cancer burden is increasing, with more patients undergoing biomarker testing in order to access more targeted and effective therapies.

Clearstate newsletter

Sign up to our newsletter for insights into key market data, trends and developments across IVD and Surgical segments from our specialists and analysts.